Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario R Ehlers

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Peptides|July 16, 2003
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardiumMohammad Kavianipour, Mario R Ehlers, Klas Malmberg, et al.
Clinical Therapeutics|May 23, 2016
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL TrialAshley Pinckney, Mark R Rigby, Lynette Keyes-Elstein, et al.
Pharmacological Reviews|September 21, 2019
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart FailureLauren B Arendse, A H Jan Danser, Marko Poglitsch, et al.
Pediatric Diabetes|February 24, 2018
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokineticsGordon C Weir, Mario R Ehlers, Kristina M Harris, et al.
European Journal of Immunology|November 1, 2015
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetesJames E Tooley, Nalini Vudattu, Jinmyung Choi, et al.
Transplantation|February 16, 2017
Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGsApolline Salama, Gwénaëlle Evanno, Noha Lim, et al.
Oncotarget|January 20, 2018
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapyRon Amon, Shani Leviatan Ben-Arye, Limor Engler, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Diabetes|January 1, 2016
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD MiceRonald G Gill, Philippe P Pagni, Tinalyn Kupfer, et al.
Diabetologia|April 8, 2016
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trialStephen E Gitelman, Peter A Gottlieb, Eric I Felner, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Peptides|July 16, 2003
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardiumMohammad Kavianipour, Mario R Ehlers, Klas Malmberg, et al.
Clinical Therapeutics|May 23, 2016
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL TrialAshley Pinckney, Mark R Rigby, Lynette Keyes-Elstein, et al.
Pharmacological Reviews|September 21, 2019
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart FailureLauren B Arendse, A H Jan Danser, Marko Poglitsch, et al.
Pediatric Diabetes|February 24, 2018
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokineticsGordon C Weir, Mario R Ehlers, Kristina M Harris, et al.
European Journal of Immunology|November 1, 2015
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetesJames E Tooley, Nalini Vudattu, Jinmyung Choi, et al.
Transplantation|February 16, 2017
Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGsApolline Salama, Gwénaëlle Evanno, Noha Lim, et al.
Oncotarget|January 20, 2018
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapyRon Amon, Shani Leviatan Ben-Arye, Limor Engler, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Diabetes|January 1, 2016
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD MiceRonald G Gill, Philippe P Pagni, Tinalyn Kupfer, et al.
Diabetologia|April 8, 2016
Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trialStephen E Gitelman, Peter A Gottlieb, Eric I Felner, et al.
Pageof 3